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1. Introduction  
Dysglycemia is common in critically ill patients. Both hyperglycemia and hypoglycemia are 
independent risk factors for increased morbidity and mortality. Hypoglycemia severity may 
even have a ‘dose-response’ relationship with increased mortality(Bagshaw et al., 2009). 
Acute hypoglycemia induces a systemic, counter-regulatory stress response that leads to an 
increase in blood norepinephrine, epinephrine, glucagon, growth hormone, and cortisol 
concentrations. Risk factors that are associated with the occurrence of hypoglycemia in ICU 
patients include severity of illness, strict glucose control, continuous veno-venous 
hemodialysis, decrease of nutrition without adjustment for insulin infusion, a prior 
diagnosis of diabetes mellitus, sepsis, and need for inotropic support (Arabi et al, 
2009;Krinsley & Grover, 2007;Vriesendorp et al. ,2006).  
The association between hyperglycemia and mortality seems population dependent, with 
the strongest association in patients in the cardiac, cardiothoracic and neurological 
ICU(Whitcomb et al., 2005). During acute illness, hyperglycemia might exert an even more 
deleterious effect on ICU patients without diabetes than among patients with 
diabetes(Capes et al., 2000;Krinsley 2006;Rady et al., 2005). Unlike nondiabetic patients, 
diabetic patients show no clear association between hyperglycemia during intensive care 
unit stay and mortality and markedly lower odds ratios of death at all levels of 
hyperglycemia. These findings suggest that, in critically patients with diabetes mellitus, 
hyperglycemia may have different biological and/or clinical implications(Egi et al., 2008).  
Recently, variability of glucose concentrations has been identified as an additional factor 
that may contribute to the mortality and morbidity of dysglycemia. A retrospective 
evaluation of over 7000 patients identified glycemic variability, defined as the standard 
deviation of each patient’s mean glucose level during ICU stay, as a stronger predictor of 
mortality than hyperglycemia(Egi et al., 2006). High glucose variability during ICU stay was 
associated with increased mortality in patients without diabetes, even after adjustment for 
severity of illness and mean glucose concentration(Krinsley 2009). In contrast, there was no 
independent association of glucose variability with mortality among patients with diabetes. 
Glucose variability contributes to ICU mortality and in-hospital death by increasing 
oxidative stress, neuronal damage, mitochondrial damage, and coagulation activation. 
The relation between glucose concentration and outcome is complex and not linear. The 
interaction between glucose concentrations and outcome may arise from independent and 
synergistic domains of glycemic control including central tendency (such as mean and 
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median glucose values), variability and the minimum glucose value (Mackenzie et al., 2011).  
Using these different metrics of glycemic control, a population-specific relationship between 
metrics of outcome was demonstrated in patients in a surgical, trauma, cardiac and 
neurological ICU. This relationship had a dose response component with an n-shape curve 
in neurological ICU patients, suggesting a survival advantage during hyperglycemia in 
these patients.  
Strict glycemic control may improve morbidity and mortality in critically ill patients. 
Intensive glucose control is however associated with a higher incidence of hypoglycemia 
compared to conventionally treated patients. This increased risk of hypoglycemia may limit 
the use of strict glucose control in critically ill neurological patients, since hypoglycemia is a 
well known cause of secondary brain injury. In this review we will describe the different 
aspects of dysglycemia and glycemic control in critically ill patients, with a special emphasis 
on the critically ill neurological patients. 
2. Glucose homeostasis in critically ill patients  
Glucose homeostasis is a physiologically well-balanced mechanism depending on 
coordinated and simultaneously ongoing processes involving insulin secretion by the 
pancreas, hepatic and renal glucose output and glucose uptake by splanchnic (liver and gut) 
and peripheral tissues. Cellular uptake of glucose occurs via insulin- or noninsulin-
dependent mechanisms. The noninsulin-dependent pathway is the major mechanism of 
glucose uptake in the basal state, accounting for 75-85% of the total post-prandial glucose 
uptake and is mainly directed at the brain(Gottesman et al., 1983).  
The brain plays a central role in the orchestration of the changes in blood glucose and the 
appropriate counterregulatory responses (reviewed in (Watts & Donovan, 2010)).  Some 
neurons possess specialized mechanisms that allow them to act as glucosensors and alter 
their firing rates with fluctuating ambient glucose concentrations. These neurons are 
predominantly located in the hypothalamus and hindbrain. Important glucosensing 
elements are also present in the hepatic portal/mesenteric vein, gut, carotid body and oral 
cavity. Information from the glucosensing elements is processed by neurons in the 
hypothalamus and hindbrain. These neurons regulate the counterregulatory responses and 
provide direct input to the appropriate neuroendocrine motor and preganglionic neurons in 
the hypothalamus, hindbrain, and autonomic ganglia. Their output in turn controls and/or 
modulates effector cells in the adrenal medulla (chromaffin cells), anterior pituitary 
(corticotopes and somatotropes), and pancreatic islets (┙- and ┚-cells).  
Severe illness induces a stress response with alterations in the glucose metabolism including 
enhanced peripheral glucose uptake and utilization, hyperlactatemia, increased glucose 
production, depressed glycogenesis, glucose intolerance, and insulin resistance(Mizock, 
1995). Stress hyperglycemia is caused by a highly complex interplay between 
counterregulatory hormones such as cortisol, epinephrine, norepinephrine and glucagon, 
leading to an increase in hepatic and renal glucose production and insulin resistance 
(reviewed in (Dungan et al., 2009)). The hepatic gluconeogenesis that is induced by 
glucagon, cortisol and epinephrine is the key source of glucose production. The kidney is 
responsible for approximately 20% of the glucose production under resting 
conditions(Meyer et al., 2002). During stress, however, cathecholamines can increase the 
renal contribution to glucose production up to 40% by increasing substrate availability and 
the gluconeogenic efficiency of the kidney(Meyer et al., 2003). Glucagon increases both 
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gluconeogenesis and glycogenolysis in the liver, but has no effect on the kidney. Cytokines 
such as IL-6 and TNF-┙ also contribute to the synthesis of glucose by regulation of key 
enzymes such as glucose 6-phosphatase (G6Pase) involved in the 
gluconeogenesis(Blumberg et al., 1995a;Blumberg et al., 1995b). Insulin suppresses glucose 
release in both the liver and kidney by direct enzyme activation⁄deactivation, as well as by 
reducing the availability of gluconeogenic substrates and actions on gluconeogenic 
activators. Glycogenolysis and reduced glycogen synthesis in the liver probably contribute 
only to a small extent to the stress induced hyperglycemia.  
Insulin resistance is characterized by raised plasma levels of insulin, organ-specific 
alterations in glucose utilization, and impaired insulin-mediated uptake(Brealey & Singer 
2009). The insulin resistance occurs at several levels and is mainly driven by the 
inflammatory response. TNF-┙ can activate protein kinase B, resulting in phosphorylation of 
the insulin receptor thereby reducing the glucose uptake(Fan et al., 1996;Ueki et al., 2004). In 
addition, a number of animal models measured a significant reduction in the number of 
insulin receptors(McCowen et al., 2001).   
3. Glucose in critically ill neurological patients: Friend or foe?  
3.1 Glucose is fuel for the brain 
Under normal conditions, the human brain is an obligate glucose consumer and depends 
almost entirely on the availability of systemic glucose to maintain its normal metabolism. 
Glucose concentration in brain normally shows a linear relationship to blood concentrations 
with normal human blood glucose levels ranging between 70-128 mg/dL and the 
corresponding normal brain concentrations ranging from roughly 14.4-41.4 mg/dL 
(Gruetter et al., 1998).  
Autoradiography and PET have shown that the rate of glucose consumption differs between 
brain regions, with higher values in grey matter, and also varies with time, with active areas 
capturing more glucose compared to inactive areas(Raichle & Mintun, 2006). In critically ill 
neurological patients the metabolic demand of the brain is increased, resulting in a relative 
deficiency in cerebral extracellular glucose(Bergsneider et al., 1997;Hutchinson et al., 2009).  
Glucose is transported from the blood across the endothelial cells in the blood-brain barrier 
and across the plasma membranes of neurons and glia cells. Rapid breakdown of glucose by 
the brain creates a concentration gradient between the cerebrospinal fluid and the blood, 
resulting in a driving force of glucose towards the brain. Glucose is transported to the brain 
by facilitated glucose transport that is mediated by members of the glucose transporter 
(GLUT) protein family. Several GLUT isoforms have been identified in the brain: GLUT1 is 
highly expressed on endothelial cells at the blood-brain-barrier and in astrocytes, whereas 
GLUT3 is detected in neurons and GLUT5 in microglia (Vannucci et al., 1997).  
During normal activity, glucose is the predominant energy substrate for neurons. The 
metabolic coupling between neurons and astrocytes preserves energy homeostasis in the 
brain during increased neuronal activity. Activation of neurons is accompanied by an 
increase in local cerebral blood flow, thus increasing the delivery of energy substrates. 
Glucose metabolism itself is also tightly coupled to neuronal activity: activation of astrocytes 
by glutamate, that is released by neurons, results in increased production of lactate by 
astrocytes that can be used as fuel by neurons to meet their energy demand (the astrocyte-
neuron lactate shuffle)(Pellerin et al., 2007;Pellerin & Magistretti, 2004;Rothman et al., 1999). 
This astrocyte-neuron lactate shuffle also contributes to neurotransmitter recycling and 
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restoration of neuronal membrane potentials. Recent studies indicate that the human brain 
has the capacity to support up to 10% of its energy metabolism with lactate. Lactate in 
plasma can cross the blood-brain barrier through monocarboxylate transporters(Simpson et 
al., 2007). Plasma lactate may become a significant source of fuel in conditions of increased 
plasma lactate levels or when blood glucose levels are reduced, accounting for up to 60% of 
the energy metabolism(Boumezbeur et al., 2010).  
Glycogen metabolism is also under the control of metabolic coupling. Glycogen is 
predominantly localized in the peripheral astrocytic processes surrounding the neuronal 
elements and serves as an endogenous source of energy for these cells and for neurons 
during extreme energy failure. Neurochemical signals from neurons and astrocytes trigger 
glycogenolysis. In astrocytes, glucose derived from glycogenolysis is used for both oxidative 
metabolism and for production of lactate(Benarroch, 2010). This lactate serves as an energy 
substrate for oxidative metabolism in neurons.  
Since the brain relies upon plasma glucose as its primary energy source, a reduced blood 
glucose concentration promptly induces a complex counter regulatory response aiming at 
recovery of plasma glucose concentrations. Glucagon and epinephrine are released after a 
small decrease in glucose concentration, followed by activation of the autonomic nervous 
system. This hypoglycemia induced systemic stress response is accompanied by an 
increasing cerebral blood flow and altered cerebral metabolism with increased 
glycogenolysis. Depending on the duration and severity, the effects of hypoglycemia span 
from mild changes in EEG signals to irreversible brain injury and coma. Not all neurons are 
equally sensitive to hypoglycemic injury. Neurons in the cerebral cortex and the 
hippocampus are affected preferentially, followed by neurons in the basal ganglia and the 
thalamus. Neurons in the brain stem, the cerebellum, and the spinal cord are generally 
spared, as are glial cells and white matter tracts (Auer et al., 1989). The hypoglycemic 
neuronal damage is not a direct result of energy failure but mainly caused by an excitotoxic 
amino acid mediated increase in intracellular calcium, production of reactive oxygen species 
and apoptosis (Suh et al., 2007).   
In acute brain injury, the hypoglycemic threshold is lower compared to normal brain and 
even mild hypoglycemia can induce neuroglycopenia. In patients after traumatic brain 
injury, arterial glucose levels < 108 mg/dL resulted in decreased brain glucose 
concentrations with an increased cerebral uptake of glucose(Meierhans et al., 2010). 
Microdialysis markers of brain metabolic distress were significantly reduced at brain 
glucose concentrations > 18 mg/dL, reaching the lowest levels at arterial blood glucose 
levels between 108-162 mg/dL. From this study it was concluded that arterial blood glucose 
concentrations between 108-162 mg/dL were optimal in traumatic brain injury. In addition, 
low brain glucose concentrations are associated with recurrent, spontaneous, spreading 
depolarizations in pericontusional tissue, resulting in a further reduction in brain glucose 
concentration and an ongoing brain damage (Feuerstein et al., 2010;Parkin et al., 2005).  
3.2 Glucose is toxic to the brain 
Stress-related hyperglycaemia, previously considered to be a protective physiological 
response to meet the increased demands of an injury, is associated with a poor outcome in 
critically ill patients. This association of poor outcome and hyperglycemia has been 
consistently confirmed across multiple studies and different disease entities such as 
traumatic brain injury (Jeremitsky et al., 2005;Lam et al., 1991;Rovlias & Kotsou, 2000;Salim 
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et al., 2009), intracranial hemorrhage (Fogelholm et al., 2005;Godoy et al., 2008;Godoy et al., 
2009;Godoy & Di, 2007;Kimura et al., 2007;Passero et al., 2003) and subarachnoid 
hemorrhage (Badjatia et al., 2005;Frontera et al., 2006;Kruyt et al., 2008;Kruyt et al., 
2009;Lanzino et al., 1993).   
Hyperglycemia is associated with many detrimental effects, including reduced immune 
function, increased inflammation and coagulation, and modulation of the endothelium. 
Plasma concentrations of pro-inflammatory cytokines are increased during hyperglycemia, 
while insulin reduces the pro-inflammatory cytokine response and restores the pro- and 
anti-inflammatory balance (Turina et al., 2005).  Glucose increases basal TNF and IL-6 
production in human monocytes in-vitro (Morohoshi et al., 1996). Similarly, a glucose-
dependent increased production of TNF by peripheral blood cells in-vitro after stimulation 
with lipopolysaccharide was measured, whereas glucose does not influence the production 
of the anti-inflammatory cytokine IL-10 (Hancu et al., 1998). In-vivo induced hypoglycaemia 
in hypoglycaemic human clamp models resulted in a down-modulation of 
lipopolysaccharide -induced TNF synthesis(de Galan et al., 2003). Hyperglycemia increases 
the expression of tissue factor, which has both proinflammatory and procoagulant 
functions(Brealey & Singer, 2009).  Hyperglycemia induces endothelial dysfunction through 
several damaging pathways, including the polyol/sorbitol/aldose reductase pathway, the 
protein kinase C pathway, the accumulation of non-enzymatic glycation end products and 
by increased oxidative stress, ultimately leading to increased expression of endothial 
cytokines and adhesion molecules (van den Oever et al., 2010). Insulin infusion restores 
normoglycemia in critically ill patients and improves and restores host defence, 
haemodynamics and coagulation abnormalities. 
The deleterious effects of acute hyperglycemia on brain injury has been demonstrated in a 
large number of animal studies (reviewed in (Ergul et al., 2009)). Hyperglycemia increases 
infarct volume in focal models of ischemia and aggravates necrosis in global 
ischemia/reperfusion models. In addition, hyperglycemia contributes to the vascular 
damage during ischemia/reperfusion injury, resulting in increased hemorrhagic 
transformation during reperfusion(de Court et al., 1989;de Court et al., 1988). Marked blood-
brain barrier disruption with formation of brain edema has been found in hyperglycemic 
rats after temporary and permanent middle cerebral artery occlusion(Kamada et al., 2007). 
In diabetes adaptive protective mechanisms gradually develop, protecting the subject 
against acute hyperglycemia. Diabetes promotes neovascularization, remodeling and 
increases in vascular tone limiting cerebral perfusion(Ergul et al., 2009). Resulting hypoxia 
and/or metabolic changes mediate ischemic tolerance via neuronal preconditioning but 
decreases vascular ischemic tolerance leading to increased and accelerated hemorrhagic 
transformation and development of edema in the event of an ischemic event. Acute 
hyperglycemia also increases vascular tone and disrupts vascular integrity but in the 
absence of sufficient time to stimulate adaptive protective mechanisms, the magnitude of 
neuronal damage is greater.  
Cerebral ischemia results in widespread activation of the systemic inflammatory system 
(Offner et al., 2006). Systemic inflammatory mediators such as cytokines and adhesion 
molecules can activate microglial cells and perivascular macrophages and contribute to 
irreversible brain ischemia(Bemeur et al., 2007). After the initial activation of the innate 
immune response, inflammatory cells from the periphery are mobilized and contribute to 
microvessel obstruction, edema formation, cellular necrosis and tissue infarction. 
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Hyperglycemia enhances neutrophil infiltration and increases cytokine expression in several 
animal models of cerebral ischemia and likely exacerbates the ischemic injury(Bemeur et al., 
2005).  
4. Glucose control in critically ill patients 
4.1 Intensive insulin therapy 
A number of randomized controlled trials have been performed on the effects of strict glucose 
control in critically ill patients. Two single centre trials were performed in Leuven by van den 
Berghe et al(Van den Berghe et al., 2001;Van den Berghe et al., 2006a), followed by a number of 
multicentre trials. The first Leuven trial compared maintenance of blood glucose levels 
between 80 and 110 mg/dl versus 180 and 200 mg/dl in critically ill patients in a surgical 
ICU(Van den Berghe et al., 2001). In this trial strict glucose control resulted in a 42% reduction 
in mortality compared with conventional treatment. Septic patients and patients with an ICU 
stay > 5 days showed the largest reduction in mortality. In the second trial from Leuven 
performed in medical ICU patients no mortality benefit was demonstrated in the overall 
intention to treat analysis(Van den Berghe et al., 2006a). A reduction in hospital mortality from 
52.5 to 43.0 percent was found in patients treated with intensive insulin therapy who stayed in 
the ICU for 3 days or more. Among patients treated < 3 days in the ICU, mortality was higher 
in the insulin group compared to the conventional group. The incidence of hypoglycemia was 
higher in the intervention group compared to the conventional treatment in both trials. 
Pooling the two datasets of both Leuven trials revealed that intensive insulin therapy reduced 
morbidity and mortality in a mixed surgical/medical ICU population, especially when 
continued for at least 3 days, without causing harm to patients treated for < 3 days(Van den 
Berghe et al., 2006b). The subgroup of patients with a prior history of diabetes did not appear 
to benefit. Blood glucose maintained at < 110 mg/dl was more effective that at 110-150 mg/dl, 
but also carried the highest risk of hypoglycemia.  
How strict control of blood glucose reduces morbidity and mortality is unknown, but the 
mechanism may be related either to a direct effect of normalization of hyperglycemia or to 
the concomitantly higher insulin levels. Post hoc multivariate logistic regression analysis of 
the study by van den Berghe et al. suggests that the lowered blood glucose level rather than 
the insulin dose is related to the reduction in mortality (Van den Berghe et al., 2003). Apart 
from glucose lowering, insulin has a number of nonglycemic metabolic effects that may be 
important in critical illness (reviewed in (Honiden & Inzucchi, 2010)). Insulin can modulate 
inflammation via the mannose binding lectin pathway, via NF-kB and via modulation of 
pro- and anti-inflammatory cytokines. It can  reduce free fatty acids and reverse the state of 
dyslipidemia in critical illness, regulate apotosis, prevent endothelial dysfunction and 
hypercoagulation,  decrease neutrophil chemotaxis and leukocyte adhesion and prevent 
excessive nitric oxide which may help regulate oxidative stress.  
A retrospective analysis of the databases of the two Leuven trials assessed the effect of 
intensive insulin therapy on blood glucose amplitude variation and pattern irregularity in 
critically ill patients(Meyfroidt et al., 2010). The Leuven intensive insulin therapy strategy 
increased mean daily delta blood glucose while not affecting standard deviation blood 
glucose. Increased blood glucose amplitude variation and pattern irregularity were 
associated with mortality, irrespective of blood glucose level. In contrast, the reduced 
mortality observed with intensive insulin therapy in the Leuven trials could not be 
attributed to an effect on blood glucose amplitude variation.  
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After these landmark studies by Van den Berghe in 2001 and 2006, tight glycemic control 
was adopted as standard care in a large number of ICUs. However, subsequent randomized 
controlled multicentre trials were unable to replicate the results of these landmark trials. The 
Glucontrol study compared strict glucose control (blood glucose concentrations 80-110 
mg/dL) to a target glucose between 140-180mg/dL, in an attempt to prevent the adverse 
effects of severe hyperglycemia, while reducing the risks of hypoglycemia(Preiser et al., 
2009). This multicentre study was stopped early due to the high rate of protocol violations. 
Strict glucose control failed to induce any clinical benefit, but was associated with a higher 
incidence of hypoglycemia. The VISEP trial was a multicenter, two-by-two factorial trial, 
that randomly assigned patients with severe sepsis to receive either intensive insulin 
therapy to maintain euglycemia or conventional insulin therapy and either a low-molecular-
weight hydroxyethyl starch or modified Ringer’s lactate for fluid resuscitation(Brunkhorst 
et al., 2008). After the first safety analysis, involving 488 patients  intensive insulin therapy 
was terminated early by the data and safety monitoring board, owing to an increased 
number of hypoglycemic events (12.1%), as compared with conventional insulin therapy 
(2.1%). No differences in mortality and morbidity between the intensive and conventional 
treatments groups were found, but patients in the intensive-therapy group tended to have 
longer stays in the ICU than did patients in the conventional therapy group. The NICE-
SUGAR trial was a large, international, randomized trial comparing intensive glucose 
control, with a target blood glucose range of 81 to 108 mg/dl to conventional glucose 
control, with a target < 180 mg/dl(Finfer et al. 2009).  Intensive glucose control increased the 
absolute risk of death at 90 days by 2.6 percentage points; this represents a number needed 
to harm of 38. The difference in mortality remained significant after adjustment for potential 
confounders. Severe hypoglycemia was significantly more common with intensive glucose 
control. Given this lack of reproducible results in a heterogeneous group of ICU patients, 
and concerns over excessive hypoglycemia, extremely tight glucose control cannot be 
considered standard of care in ICU patients.  
The multicentre trials were unable to replicate the findings of the 2 Leuven trials and raised 
the possibility that intensive insulin therapy may even increase the risk of mortality and 
morbidity in ICU patients. The explanation for the disparate findings seems multifactorial. 
In the Leuven studies the rate of use of total parenteral nutrition was higher compared to 
the other studies. Intensive insulin therapy may increase mortality in patients receiving 
enteral nutrition, possibly related to the adverse effects associated with hypoglycemia(Marik 
& Preiser, 2010). In turn, high dose parenteral glucose administration in the absence of 
intensive insulin therapy results in hyperglycemia with associated organ failure and death. 
In the Leuven studies, adjustments of insulin dosage were exclusively based on blood 
glucose measured on arterial blood via a point-of-care blood gas/glucose analyzer, whereas 
other studies used samples obtained from different sites and measured with different 
devices. The conventional treatment differed among the studies(Gunst & Van den Berghe, 
2010). In the Leuven studies higher glucose values were tolerated compared to the other 
trials and the beneficial effects of intensive insulin therapy in these studies may be obtained 
by preventing excessive hyperglycemia.  
4.2 Intensive insulin therapy in brain injury 
Hyperglycemia at the time of brain injury is associated with increased morbidity and 
mortality. A planned subgroup analysis in patients with isolated brain injury of the first 
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Leuven study revealed that intensive insulin therapy resulted in lower intracranial 
pressures, less seizures and a better long-term rehabilitation. Strict glucose control also 
protected general ICU patients against critical illness polyneuropathy.  
A number of small studies on glucose control in critically ill neurological patients have been 
published, but most of these trials were too small to achieve sufficient statistical power to 
demonstrate possible effects on neurological outcome or mortality. Intensive insulin therapy 
did not change the incidence of vasospasm, neurological outcome or mortality rates in 
patients with acute subarachnoid hemorrhage(Bilotta et al., 2007). A decrease in infection 
rate from 42 to 27% was observed in the patients with strict glucose control compared to 
conventional glucose control. No differences in neurological outcome or mortality rates were 
found in patients after severe traumatic brain injury(Bilotta et al., 2008;Coester et al., 2010). A 
trial in 483 patients undergoing elective or emergency brain surgery revealed that intensive 
insulin therapy significantly reduced the length of stay in the ICU (6 vs. 8 days), and the 
infection rate (25.7% vs. 39.3%) without a significant effect on neurological outcome or survival 
at 6 months(Bilotta et al., 2009). In the UK Glucose Insulin in Stroke Trial (GIST-UK) patients 
presenting within 24 hours of stroke onset were randomly assigned to receive glucose-
potassium-insulin infusion aiming at a capillary glucose between 72-126 mg/dL or no glucose 
intervention(Gray et al., 2007). The trial was stopped due to slow enrolment after 933 patients 
were recruited. There was no significant reduction in mortality or neurological disability at 90 
days, although the study was underpowered and alternative results could not be excluded. 
The Treatment of Hyperglycemia in Ischemic Stroke (THIS) trial revealed similar 
results(Bruno et al., 2008). Strict versus moderate glucose control did not improve outcome in 
patients after resuscitation from ventricular fibrillation(Oksanen et al., 2007).  Intensive or 
conventional control of blood glucose levels in mechanically ventilated adult neurologic ICU 
patients resulted in a non-significant increase in mortality in the patients in the intensive 
insulin group (36 vs 25%), with no differences in functional outcome(Green et al., 2010).  
The results from the studies on strict glucose control in unselected critically ill patients may 
not be directly applicable to patients with critical neurological disease because of the high 
sensitivity of the brain to the effects of hypoglycemia. Tight glucose control was complicated 
by an increased number of hypoglycemic events in all trials in critically ill neurological 
patients. Since studies in patients with acute brain injury did not show a beneficial effect of 
strict glucose control on mortality or neurological outcome, the markedly increased risk of 
hypoglycemia limits the safe use of intensive insulin therapy these patients.  
5. Glucose monitoring in the ICU setting 
Detection of hypoglycemia is difficult in ICU patients since these patients are often sedated 
and incapable of communicating, thereby masking clinical symptoms and signs. Frequent 
glucose measurement is therefore required to titrate the amount of insulin and detect episodes 
of hypoglycemia. For practical reasons bedside point of care (POCT) devices are frequently 
used. The accuracy of the POCT monitoring is influenced in several ways, including both 
preanalytic and analytic parameters. Glucose concentrations may differ according to the blood 
sampling site (venous, arterial or capillary blood). In critically ill patients, capillary blood 
glucose measured by fingerstick is inaccurate(Critchell et al., 2007;Kanji et al., 2005).  Capillary 
sampling led to both overestimation(Kanji et al., 2005)  and underestimation(Atkin et al., 1991) 
of blood glucose values. The presence of shock, use of vasopressors and upper extremity 
edema were associated with the occurrence of inaccurate readings.  
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The reliability of the POCT devices itself in critically ill patients is also poor. In a prospective 
observational study the performance of 3 different POCT devices was tested and compared 
with the glucose oxidase method in arterial blood samples(Hoedemaekers et al., 2008). To 
minimize  preanalytical bias the measurements were performed simultaneously by an 
experienced laboratory technician under controlled circumstances using a single arterial 
blood sample.  Paired samples from all 3 tested devices were inaccurate in 4.9-13.4% of 
measurements. Inaccurate glucose readings were most frequently falsely elevated, and 
occurred over the entire range of blood glucose values. Patients with inaccurate POCT glucose 
results were significantly older, had a higher disease severity score, and a higher ICU mortality 
compared with patients with accurate glucose values. The mechanism underlying the 
differences in glucose values between the different POCT systems and the glucose oxidase 
method in critically ill patients is unknown. Accu-Chek uses the glucosedehydrogenase- 
pyrroloquinolinequinone method for glucose determination, which is not specific for glucose. 
This method misinterprets maltose, icodextrine (which is converted to maltose), galactose, and 
xylose as glucose, leading to erroneously elevated glucose levels (Schleis, 2007). In addition, a 
large number of drugs commonly used in the treatment of critically ill patients, such as 
acetaminophen, dopamine, and mannitol, interfere with a number of POCT test systems. 
Changes in hematocrit concentration can influence the results of POCT measurements. 
Depending on the point-of-care testing device that is used both overestimation and 
underestimation of the glucose values can occur in patients with low hematocrit levels(Karon 
et al., 2008). Glucose measurement in the ICU setting using these bedside devices can be 
inaccurate and potentially dangerous: inaccurate glucose readings are most frequently falsely 
elevated, resulting in misinterpretation of high glucose values with subsequent inappropriate 
insulin administration or masking of true hypoglycemia.  
In the past decade continuous glucose measurement devices have been developed in order 
to make glycemic management  safer and more efficient. Due to concerns regarding altered 
perfusion in critical illness, many have questioned the accuracy of such devices in ICUs. So 
far, both excellent and poor performance has been reported in ICU patients (Bridges et al,. 
2010;Corstjens et al., 2006;Holzinger et al., 2009;Price et al., 2008). Until these matters are 
solved, continuous monitoring of interstitial glucose values should be used with caution in 
the ICU.  
6. Conclusion 
Glucose control in the ICU is markedly different from that in an out-patient clinic. Severe 
illness induces dysglycemia, with potential detrimental effects of low, high and variable 
glucose values. The injured brain is particularly susceptible for changes in glucose 
concentrations. strict glucose control is not proven beneficial in neurological ICU patients 
and has a unacceptable risk of hypoglycemia. Glucose control in  the neurological ICU 
should be focused on maintenance of a steady level of glucose between 8-10 mmol/l, 
avoiding large fluctuations. Glucose monitoring in  neurological ICU patients is difficult and 
requires special attention.  
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